TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Kivo Health raised $10 million in a Series A round led by Allumia Ventures, bringing its total financing to $16 million. The Seattle company says it will use the funds to expand its virtual home-care program for chronic lung disease nationwide and plans to reach tens of thousands of patients in two years. Its reported cost savings and patient outcomes are company claims, not independently verified in the source report.
Seattle-based Kivo Health has raised $10 million in Series A financing to expand its virtual home-care service for people with chronic lung diseases, starting with COPD. The round brings the company’s total financing to $16 million, according to Home Health Care News, and Kivo says it plans to expand nationwide.
Allumia Ventures led the round, with additional investment from Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures, the report said. Kivo intends to use the funding to grow its reach and, over time, extend its care model to other high-cost chronic illnesses.
Kivo’s program combines equipment for use at home with remote care from respiratory therapists. After enrolling, patients receive a kit that includes a tablet, an oxygen monitor and exercise bands. They meet virtually with a therapist to discuss breathing symptoms and develop a personal care plan.
According to Kivo’s website, participants then join small-group virtual sessions with respiratory therapists twice a week for nine weeks. The sessions cover breathing techniques, targeted exercises and information about managing COPD. The source report says the program is covered by Medicare, Medicaid and several commercial health plans, including UnitedHealthcare, Humana, Blue Cross, Aetna and Priority Health.
Funding Targets Wider Home COPD Care
The financing gives Kivo capital to pursue national expansion of a service designed to help patients manage COPD at home between clinical visits. If the company reaches more patients, the program could provide an additional way to access respiratory support without relying solely on in-person appointments. The funding announcement, however, does not establish how quickly expansion will occur or how many new markets will be served.
Kivo’s approach also reflects a broader healthcare business question: whether remote, structured support can help people with chronic conditions avoid some costly episodes of care. The company says its service aims to reduce hospitalizations and improve quality of life, but those are company-described goals. The report does not provide independent results or study methods to verify the claimed effects.
The financial stakes are part of the company’s pitch to health plans. Kivo says its program reduces total healthcare spending by $8,245 per member per year, attributing the savings to fewer hospitalizations, emergency-room visits and nursing-home days. That figure is a company claim; the source material does not specify the analysis period, comparison group or methodology.
Products Worth Considering
Fitbit Sense 2 Health and Fitness Smartwatch (Lunar White/Platinum)
Levoit Core 400S-P Smart Air Purifier for Large Rooms
Fitbit Charge 6 Fitness Tracker – Porcelain/Silver
As an affiliate, we earn on qualifying purchases.
How Kivo’s COPD Program Works
Kivo describes itself as an AI-powered virtual home-care provider for chronic lung disease, with COPD as its starting point. Its care model combines technology used in the home with therapist-led assessments and group sessions. The company says the aim is to support older adults with earlier intervention and ongoing management between clinical visits.
The funding adds to Kivo’s previous financing, bringing its reported total to $16 million. The company’s chief executive told Home Health Care News that Kivo has delivered tens of thousands of sessions and provided access to care for thousands of patients. Those figures and the related outcome claims were supplied by the company in response to the publication.
Kivo has said the next stage is to broaden both its geographic reach and, eventually, the conditions its program addresses. Its current offering is focused on COPD care; the source report does not name specific additional illnesses or give a timetable for launching services for them.
“We have delivered tens of thousands of sessions, providing thousands of patients access to care that improves symptoms and saves health plans money by reducing unnecessary hospitalizations, ER visits and nursing home days.”
— Victor Sadauskas, Kivo Health co-founder and CEO, in an email to Home Health Care News
Expansion Scale and Savings Evidence
The announcement does not detail how the $10 million will be allocated, which markets Kivo will enter first or how many patients it currently serves. Its goal of reaching tens of thousands of patients within two years is a company plan, and the source report does not identify milestones for tracking progress.
There is also limited detail about the evidence behind the company’s stated effects. The report does not describe the patient population, study design or comparison baseline for claims about improved symptoms, fewer hospital visits or $8,245 in annual savings per member. The reported coverage by health plans does not, by itself, establish the program’s clinical effectiveness or the savings achieved for members.
Kivo has said it wants to adapt its model to other costly chronic illnesses, but the company has not identified those conditions or announced launch dates in the source material. The extent of any role played by its AI technology in individual care decisions is also not described.
Kivo’s Two-Year Growth Goal
Kivo says it plans to use the financing to expand nationwide and provide care to tens of thousands of patients over the next two years. The company has not provided a market-by-market rollout schedule in the reported announcement. Further details on new locations, staffing and patient enrollment would clarify the pace and scope of the expansion.
The company also expects to explore extending its care model beyond COPD. Any new condition-specific programs, along with evidence supporting their outcomes and costs, would be subsequent developments; none is specified in the source report.
Key Questions
How much did Kivo Health raise?
Kivo raised $10 million in Series A financing. The round brings its reported total financing to $16 million.
Who led the funding round?
Allumia Ventures led the round. Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures also participated, according to Home Health Care News.
What care does Kivo provide?
Kivo’s current program focuses on virtual home care for COPD. Patients receive a home kit and meet remotely with respiratory therapists for assessment and a nine-week series of group sessions, according to the company’s website.
What does Kivo plan to do with the funding?
Kivo says it will use the funding to expand nationwide and aims to serve tens of thousands of patients within two years. It also plans to explore adapting its model to other high-cost chronic illnesses, though it has not named them.
Are Kivo’s reported savings independently verified?
The source report attributes the claim of $8,245 in annual savings per member to Kivo. It does not provide independent verification, the calculation method or a comparison baseline.
Source: homehealthcarenews.com
